Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

AUDUBON, Pa. - Globus Medical , Inc. (NYSE: NYSE:GMED), a prominent musculoskeletal solutions company with a market capitalization of $11.81 billion and an "GREAT" financial health rating according to ...

Sees FY25 revenue $2.66B-$2.69B, consensus $2.66B. The company said, “The Company established its full year 2025 revenue guidance range of $2.66 billion to $2.69 billion and fully diluted non ...

Consensus $2.5B. “2024 was an exceptional year of execution and achievement for Globus Medical (GMED). With the NuVasive merger, we believe we created the strongest sales force and best product ...

This leads investors to also remain optimistic about rising dividends in the future. Globus Medical has a better P/E ratio of 133.53 than the aggregate P/E ratio of 63.4 of the Health Care ...

On Thursday, BofA Securities analyst Craig Bijou upgraded shares of Globus Medical (NYSE:GMED), a medical device company, from Underperform to Neutral and increased the price target to $97 from $80.